Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. 경증에서 중등도의 코로나19에 아지스로마이신을 포함하거나 포함하지 않은 하이드록시클로로퀸
| ORIGINAL ARTICLE FROM NEJM |
| Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 |
| Alexandre B. Cavalcanti and Others |
| Patients with confirmed or suspected Covid-19 were randomized to hydroxychloroquine with azithromycin, hydroxychloroquine alone, or usual care. The primary outcome was clinical status at 15 days using a seven-level ordinal scale. There was no significant difference between groups in the primary outcome. |